INmune Bio, Inc. INMB 深 滬
等待開盤 06-25 09:30:00 美东时间
1.35
-0.070
-4.93%
華盛通- 最 高1.54
- 今 開1.43
- 成交量 27.35万股
- 最 低 1.35
- 昨 收 1.42
- 總市值 3589.01万
- 52周最高 3.244
- 市盈率 靜 --
- 換手率 1.03%
- 52周最低 1.09
- 委 比 -37.73%
- 總股本 2658.53万
- 歷史最高 30.37
- 量 比 0.87
- 振 幅 13.38%
- 歷史最低 1.09
- 每 手 1
- 風險率 0.78%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Terra Innovatum Global N.V. GAAP EPS of $9.74
Terra Innovatum Global N.V. press release (NKLR): FY GAAP EPS of $9.74. Cash and cash equivalents were $102.9 million as of December 31, 2025, compared to $2.15 million as of September 30, 2025, prior...
06-16 05:43
INmune Bio Announces Results From Exploratory Chi-Separation MRI Imaging Analyses From MINDFuL Phase 2 Clinical Trial Of XPro In Patients With Early Alzheimer's Disease
XPro1595 showed a highly significant treatment effect in the full mITT population (p=0.0028; d=0.46; n=200), demonstrating broad tissue-level target engagement and treatment-related biological effect.Efficacy was further
06-02 20:16
电话会总结 ｜ INmune Bio(INMB)2025财年Q4业绩电话会核心要点
<span style="color:#999999;">编者按：聚焦公司高管观点与展望，深挖业绩背后的信息，助力投资者把握先机。</span><blockquote><p><span style="color:#fa1432;"><strong>业绩回顾</strong></span></p></blockquote><p>• 根据INmune Bio业绩会实录，以下是财务业绩回顾摘要： ## 1. 财务业绩 **净亏损表现：** 2025年归属于普通股股东的净亏损约为4,590万美元，较2024年的4,210万美元有所扩大。 **研发支出：** 2025年研发费用总计约2,070万美元，较2024年的3,320万美元显著下降，主要由于阿尔茨海默病试验相关费用减少。 **管理费用：** 2025年一般管理费用约为1,030万美元，较2024年的950万美元小幅上升。 **资产减值：** 公司在2025年对无形资产进行了1,650万美元的全额减值，原因是阿尔茨海默病试验未能达
06-02 12:30
INmune Bio shares are trading higher after the company announced that the FDA granted the fast Track designation to XPro
INmune Bio shares are trading higher after the company announced that the FDA g...
05-14 21:30
Venu Holding plans $300M Chattanooga amphitheater project
Venu Holding (VENU) on Tuesday said it entered an agreement to purchase a 15-acre site in Chattanooga, Tennessee, for the planned development of Sunset Amphitheater Chattanooga, a next-generation live...
05-12 23:18
Sidus Space prices $58.5M offering at $4.35 per share
Space and defense technology firm Sidus Space (SIDU) announced the pricing of a direct offering of ~13.4M shares at an offering price of $4.35 per share. Gross proceeds target $58.5M before placement ...
04-20 12:50
Sidus Space reports FY results
Sidus Space press release (SIDU): FY net loss was $29.5 million, compared to a net loss of $17.5 million for the same period in 2024. The increase includes a $4.5 million non-cash impairment charge re...
04-01 18:12
Inmune Bio Earnings Call Balances Progress and Risk
Inmune Bio (($INMB)) has held its Q4 earnings call. Read on for the main highli...
04-01 08:26
Tilray Q3 earnings: What to expect
Tilray (TLRY) is expected to report an 8% jump in its revenue during its third-quarter results on March 31, before the market opens. The consensus EPS Estimate is $0.07, while revenue is expected to c...
03-31 22:34
T1 Energy misses top-line and bottom-line estimates; introduces FY26 outlook
T1 Energy press release (TE): Q4 GAAP EPS of -$0.70 misses by $0.69. Revenue of $358.55M (vs. $2.94M Y/Y) misses by $9.65M. As of December 31, 2025, T1 had cash, cash equivalents, and restricted cash ...
03-31 18:06
